Proprietary Product Development
Arecor is committed to leveraging its ArestatTM platform to develop a portfolio of proprietary products enabling improved treatment for diabetes care via the innovative reformulations of approved proteins and peptides.
Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would simply not be possible using conventional formulation science.
- PROPRIETARY DIABETES
What is Diabetes?
Diabetes is a chronic condition that affects the body’s ability to control blood sugar level. If left untreated it can lead to serious health complications.
Ultra-Rapid Acting Insulin
Significantly faster onset of action
Improved glycemic control
Desired advancement for artificial pancreas
Ultra-Concentrated Rapid Acting Insulin
Critical for miniaturisation of delivery devices
Superior fast acting insulin for high dose users
High concentration antibodies
Most biotherapeutic products in development are monoclonal antibodies or related…
Lyophilised powder to liquid switch
There is a clear need within the pharmaceutical industry to…
Intravenous to subcutaneous switch
There are a broad range of biotherapeutic products both on…
Differentiated biosimilars with IP Protection
The biosimilars market is a complex, highly competitive yet significant…
INSULINS & OTHER DIABETES PEPTIDES Arecor is leveraging its unique…
Most biotherapeutic products, particularly in liquid form, require refrigeration for…
Latest News and Events
5th December 2019
Arecor announces positive headline results for the first phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin
18th November 2019
Arecor to present at the sixth China healthcare summit 2019 in Shanghai, China
13th November 2019
Proactive Investors interview with Arecor CEO Sarah Howell
7th - 10th January 2019
JPMorgan 2019, San Francisco, 7-10 January 2019